Medigen Biotechnology Corp. (TPEX:3176)

Taiwan · Delayed Price · Currency is TWD

37.75

-0.80 (-2.08%)

Sep 24, 2026, 1:30 PM CST

Market Cap	5.26B +32.0%
Revenue (ttm)	1.27B -22.0%
Net Income	-252.36M
EPS	-1.81
Shares Out	139.31M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	604,047
Open	38.45
Previous Close	38.55
Day's Range	37.15 - 38.60
52-Week Range	28.00 - 43.60
Beta	0.31
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 12, 2026

About Medigen Biotechnology

Medigen Biotechnology Corp., a biopharmaceutical company, engages in the research and development of new drugs and vaccines, cell therapy, advanced nucleic acid testing, generic drugs, medical beauty, and vaccine-related products in Taiwan. It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells. It also develops OBP-301 that has completed Phase I clinical trials in combination with esophageal cancer in Japan; is in Phase I clinical trials in combination with immune checkpoint inhibitor... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1990

Country Taiwan

Stock Exchange Taipei Exchange

Ticker Symbol 3176

Full Company Profile

Financial Performance

In 2025, Medigen Biotechnology's revenue was 1.58 billion, an increase of 15.28% compared to the previous year's 1.37 billion. Losses were -108.80 million, -46.84% less than in 2024.

Financial Statements